The utility and limitations of ¹⁸F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review

References

• Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d’Etude des Lymphomes de l’Adulte”) study. Am J Surg Pathol 1996;20:877–888.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Piccaluga PP. Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies. Curr Oncol Rep 2011;13:407–415.
   PubMed Web of Science ®Google Scholar
• Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011;118:2659–2669.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997;15:1646–1653.
   PubMed Web of Science ®Google Scholar
• Hicks RJ, MacManus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005;35:165–175.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29:1844–1854.
   PubMed Web of Science ®Google Scholar
• Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527–533.
   PubMed Web of Science ®Google Scholar
• Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626–1632.
   PubMed Web of Science ®Google Scholar
• Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514–1523.
   PubMed Web of Science ®Google Scholar
• Pregno P, Chiappella A, Bello M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:2066–2073.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010;28:1896–1903.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851–862.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003;102:3871–3879.
   PubMed Web of Science ®Google Scholar
• Martelli M, Ferreri AJM, Johnson P. Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol 2008;68:256–263.
   PubMed Web of Science ®Google Scholar
• Cheah CY, Hofman MS, Dickinson M, et al. Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 2013;109:312–317.
   PubMed Web of Science ®Google Scholar
• Meignan M, Gallamini A, Meignan M, et al. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 2009;50:1257–1260.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013;368:1408–1416.
   PubMed Web of Science ®Google Scholar
• Koller CA, Kantarjian HM, Thomas D, et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997;11:2039–2044.
   PubMed Web of Science ®Google Scholar
• Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664–670.
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012;17:239–249.
   PubMed Web of Science ®Google Scholar
• Soumerai JD, Hellmann MD, Feng Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014;55:538–543.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era. Blood 2012;120(Suppl. 1): Abstract 303.
   PubMed Web of Science ®Google Scholar
• Avril N. GLUT1 expression in tissue and 18F-FDG uptake. J Nucl Med 2004;45:930–932.
   PubMed Web of Science ®Google Scholar
• Prahladan M, Grigoropoulos NF, Munisamy S, et al. Interim PET scan does not predict outcome in primary mediastinal B cell lymphoma treated with R DA EPOCH. ASH Annual Meeting Abstracts 2012;120:4846.
   Google Scholar
• Prahladan M, Grigoropoulos NF, Munisamy S, et al. Interim PET scan does not predict outcome in primary mediastinal B cell lymphoma treated with R DA EPOCH. Blood 2012;120(Suppl. 1): Abstract 4846.
   PubMed Web of Science ®Google Scholar
• Algrin C, Berenger N, Chevret S, et al. Interim-positron emission tomography with [18F]fluorodeoxyglucose (interim-PET) evaluation in mediastinal lymphoma including Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBL). Blood 2010;116(Suppl. 1): Abstract 2860.
   Google Scholar
• Chong EA, Chekol S, Shah NN, et al. The role of PET imaging for predicting treatment failure in primary mediastinal B-cell lymphoma. Blood 2013;122(Suppl. 1): Abstract 4302.
   Google Scholar
• Ceriani L, Zucca E, Zinzani PL, et al. Role of positron emission tomography (PET/CT) in primary mediastinal large B cell lymphoma (PMLBCL): preliminary results of an international phase II trial (IELSG-26 Study) conducted on behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. Blood 2012;120(Suppl. 1): Abstract 1566.
   Google Scholar
• Vassilakopoulos TP, Pangalis GA, Rondogianni PH, et al. The role of PET/CT after rituximab-CHOP (R-CHOP) in primary mediastinal large B-cell lymphoma (PMLBCL): response assessment, prognostic significance and implications for subsequent radiotherapy (RT). Haematologica 2013;98(Suppl. 1): Abstract 135.
   Google Scholar
• Zinzani PL, Casadei B, Pellegrini C, et al. The role of rituximab and PET in the treatment of primary mediastinal B-cell lymphoma. Hematol Oncol 2013;31(Suppl. 1):128.
   Google Scholar
• Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004;90:372–376.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol 2008;26:171–178.
   PubMed Web of Science ®Google Scholar
• Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 2013;87:311–316.
   PubMed Web of Science ®Google Scholar
• Martelli M, Zucca E, Gospodarowicz M, et al. A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol 2013;31(Suppl. 1):140.
   Google Scholar
• Moskowitz C, Hamlin Jr PA, Maragulia J, Meikle J, Zelenetz AD. Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01-142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma. ASH Annual Meeting Abstracts 2010;116:420.
   Google Scholar